Bioventures, Cambridge, MA
Broad-based life sciences fund based on established relationships of managing directors and advisors which seeks out early and mid-stage investment opportunities in the biosciences and health care industries and provides council and critical services to subsidiary companies. link
Den X, Ltd. Develops and markets the world's most advanced image-guided technology for dental training and clinical implementation. Den X's exclusive 3-D graphics and real-time image processing are used by leading dental institutions in the US, Europe and Asia for maximum precision and effectiveness. link
Metabolix is using life science technologies to forge new links between agriculture and industry, responding to society's call for renewable, sustainable products. The new links, which are provided by a class of natural polymers, known as PHAs, allow photosynthesis to be harnessed directly to manufacture plastics, chemicals, and coatings, from plant crops and by fermentation. Metabolix inserts these PHA links into the agricultural chain using a platform technology based on the emerging science of metabolic engineering. In this process, proprietary genes direct the metabolism of plants and bacteria to these polymers, which accumulate as storage compounds, like starch and oils. After harvesting, these PHA storage compounds may then be used directly as plastics and coatings, or converted to other useful chemicals, meeting today's environmental materials challenge. link
Microbia develops antimicrobial drugs and microbial drug production technologies based on proprietary knowledge of the physiological changes made by microbes as they sense and adapt to changes in their environment. The Company's initial priorities are biofilm inhibition factors and anti-fungal drugs; and technology which enhances the production of microbially produced pharmaceuticals and fine chemicals. link
Real-Time Radiography is developing the next generation direct Digital Radiography (DR) detectors based on its proprietary mercuric iodide x-ray photoconductor technology. The company manufactures unique detectors that are capable of operating in both dynamic (fluoroscopic) and static imaging applications. The detector's exceptional sensitivity to x-rays, significant cost advantages, and low voltage operation make it unsurpassed in providing high image quality at low doses of radiation and at a reduced expense to the end user. link
Organ Recovery Systems is a company developing technologies to improve the quality and quantity of organs for transplantation. Organ Recovery Systems markets LifePort, a growing family of devices that establishes a new continuum of care for ex vivo organs. The LifePort Kidney Transporter is now in routine use worldwide and has been recognized for excellence in design. link
Seedlings Enterprises
Newton, MA
Creates equity value in new medical device businesses through sale of technology platforms product lines to large corporations and from royalties associated with the sale of individual products.
Tigris Pharmaceuticals, Inc. is a venture-backed clinical-stage biopharmaceutical company that commercially develops innovative products for the treatment of important unmet medical needs in cancer and infectious diseases. Tigris is focusing its efforts on the development, testing and commercialization of its lead compound, A-007, as a non-invasive treatment for both pre-cancerous HPV-induced lesions and for invasive epithelial cancers. A key component of Tigris' strategy is to acquire global rights to additional product candidates in oncology and infectious diseases, while continuing to use its technology platform to develop and commercialize new products and line extensions. link
Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of human antibodies into novel therapeutic drugs to treat a variety of diseases. Our proprietary ACTIVMAB antibody discovery technology allows for the direct selection of high affinity, fully human monoclonal antibodies that would be difficult or impossible to identify using other systems. Unique to this technology is the capability to recover fully functional human antibodies from libraries expressed in mammalian cells. link
Click here to view former portfolio companies.